LDN Social Media
Get connected with us on social networks
Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for Symptomatic Mesenteric Panniculitis
J Clin Gastroenterol
October 2015
https://www.academia.edu/28700218/Initial_Findings_of_an_Open_Label_Trial_of_Low_Dose_Naltrexone_for_Symptomatic_Mesenteric_Panniculitis
Three adults with symptomatic mesenteric panniculitis were treated with 4.5mg of LDN nightly for 12 weeks. Clinical response was defined as diminution of symptoms at 4 and 8 weeks. A biochemical response was reduction in the ESR or CRP at 4 weeks. All had decrease in MPSAS at 4 weeks, 2 of 3 had decrease at 8 weeks
LDN was safe and well tolerated.